106.13

0.00% 0.00

After Hours: 106.10 -0.03 -0.03%

Novo Nordisk Adr (NVO)

Overview News Price History Option Chain Why NVO Down? Discussions Forecast Stock Split Dividend History

Novo Nordisk Adr stock is traded at $106.13, with a volume of 3.38M. It is up +0.00% in the last 24 hours and down -6.39% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Previous Close:

$106.13

Open:

$105.79

24h Volume:

3.38M

Relative Volume:

0.72

Market Cap:

$471.56B

Revenue:

$39.36B

Net Income/Loss:

$13.79B

P/E Ratio:

44.08

EPS:

2.4077

Net Cash Flow:

$9.83B

1W Performance:

+0.82%

1M Performance:

-6.39%

6M Performance:

-21.99%

1Y Performance:

+2.18%

1-Day Range:

$104.96

$106.13

1-Week Range:

$101.51

$107.70

52-Week Range:

$94.73

$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Name

Novo Nordisk Adr

Sector

Healthcare (1200)

Industry

Drug Manufacturers - General (18)

Phone

Address

Employee

72,000

Twitter

@novonordisk

Next Earnings Date

2024-12-06

Latest SEC Filings

NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVO Novo Nordisk Adr	106.13	471.56B	39.36B	13.79B	9.83B	2.4077
LLY Lilly Eli Co	788.19	752.65B	40.86B	8.37B	-2.28B	5.4193
JNJ Johnson Johnson	155.40	353.35B	87.70B	14.68B	19.03B	13.47
ABBV Abbvie Inc	183.08	323.72B	55.53B	5.12B	15.62B	3.65
MRK Merck Co Inc	103.12	260.72B	63.17B	12.15B	14.84B	1.80

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-24	Initiated	Goldman	Buy
Apr-12-24	Initiated	BMO Capital Markets	Outperform
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight
Oct-02-23	Initiated	Argus	Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy
Jan-25-22	Downgrade	Liberum	Hold → Sell
Dec-20-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-21	Downgrade	Deutsche Bank	Buy → Hold
Jan-20-21	Downgrade	Credit Suisse	Outperform → Neutral
Jan-15-21	Initiated	Deutsche Bank	Buy
Sep-29-20	Initiated	Berenberg	Hold
Jul-06-20	Downgrade	BofA Securities	Buy → Neutral
May-11-20	Downgrade	UBS	Buy → Neutral
May-04-20	Initiated	Cowen	Market Perform
Mar-16-20	Upgrade	BofA/Merrill	Neutral → Buy
Jan-03-20	Downgrade	Guggenheim	Buy → Neutral
Nov-18-19	Upgrade	Barclays	Equal Weight → Overweight
Sep-17-19	Upgrade	Citigroup	Neutral → Buy
Aug-30-19	Downgrade	Jefferies	Hold → Underperform
Jun-20-19	Downgrade	Deutsche Bank	Buy → Hold
Jun-11-19	Upgrade	Barclays	Underweight → Equal Weight
Apr-29-19	Upgrade	Credit Suisse	Neutral → Outperform
Jan-29-19	Initiated	Exane BNP Paribas	Outperform
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Dec-29-17	Upgrade	JP Morgan	Underweight → Neutral
Dec-06-17	Upgrade	BofA/Merrill	Neutral → Buy
Dec-01-17	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-25-17	Downgrade	Exane BNP Paribas	Outperform → Neutral
Sep-06-17	Upgrade	BofA/Merrill	Underperform → Neutral

View All

Novo Nordisk Adr Stock (NVO) Latest News

Nov 27, 2024

European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN

Nov 27, 2024

Nov 26, 2024

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs - Benzinga

Nov 26, 2024

Nov 20, 2024

Biopharma Stock Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges - Morningstar

Nov 08, 2024

Nov 06, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Nov 06, 2024

NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View - Yahoo Finance

Nov 06, 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading - MSN

Nov 06, 2024

Novo Nordisk ADR earnings beat by $5.24, revenue topped estimates - Investing.com Australia

Nov 06, 2024

Nov 02, 2024

Thanks To Wall Street, Novo Nordisk Stock Is Now A Buy - Barchart

Nov 02, 2024

Oct 21, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN

Oct 21, 2024

India Subcutaneous Drug Delivery Devices Market Size & Outlook, 2030 - Grand View Research

Oct 21, 2024

Oct 18, 2024

Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail

Oct 18, 2024

Oct 16, 2024

NVO: 3 European Stocks to Buy as the Region Recovers - StockNews.com

Oct 16, 2024

Oct 11, 2024

NVO’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News

Oct 11, 2024

Oct 09, 2024

Market cap of Novo Nordisk ADR [NVO] reaches 391.26B – now what? - The DBT News

Oct 09, 2024

Analyzing Novo Nordisk ADR (NVO) After Recent Trading Activity - Knox Daily

Oct 09, 2024

Monitoring Melco Resorts & Entertainment Ltd ADR (MLCO) after recent insider movements - Knox Daily

Oct 09, 2024

Oct 07, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine

Oct 07, 2024

Oct 03, 2024

Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 — Data Talk - Morningstar

Oct 03, 2024

Oct 02, 2024